Demonstrated efficacy

92% of MAVENCLAD patients (vs. 87% of the placebo group) completed the full 96-week study. 3.5% of MAVENCLAD patients discontinued the study due to AEs.^1,2

§ The 5.25 mg/kg dosage regimen is not available.

¶ Combined unique lesions were defined as new GD+ T₁-weighted lesions or new nonenhancing or enlarging T₂-weighted lesions (without double-counting).  

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; MRI=magnetic resonance imaging; RRMS=relapsing-remitting multiple sclerosis

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.¹

† 10^th percentile of time to event.

1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.